Fractional exhaled nitric oxide in clinical trials: An overview

Advances in Experimental Medicine and Biology

Volumn 788, Issue , 2013, Pages 237-245

  Häussermann, Sabine ^a   Kappeler, Dominik ^a   Schmidt, Anje ^a   Siekmeier, Rüdiger ^b  

^a Inamed GmbH   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Asthma control; Bioequivalence; Clinical trial; Fractional exhaled nitric oxide; Inhaled corticosteroids; Pharmacodynamics

Indexed keywords

CORTICOSTEROID; FRACTIONAL EXHALED NITRIC OXIDE; NITRIC OXIDE; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; BIOEQUIVALENCE; BREATH ANALYSIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EOSINOPHILIC AIRWAY INFLAMMATION; FORCED EXPIRATORY VOLUME; HUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION;

EID: 84881045304     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-6627-3_34     Document Type: Article

References (60)

1. ATS/ERS. (1999). Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. American Journal of Respiratory and Critical Care Medicine, 160(6), 2104-2117.
2. ATS/ERS. (2005). Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. American Journal of Respiratory and Critical Care Medicine, 171(8), 912-930.
3. Avital, A., Uwyyed, K., Berkman, N., Bar-Yishay, E., Godfrey, S., & Springer, C. (2003). Exhaled nitric oxide is age-dependent in asthma. Pediatric Pulmonology, 36(5), 433-438. (Pubitemid 37296705)
4. Beck-Ripp, J., Griese, M., Arenz, S., Köring, C., Pasqualoni, B., & Bufler, P. (2002). Changes of exhaled nitric oxide during steroid treatment of childhood asthma. European Respiratory Journal, 19(6), 1015-1019. (Pubitemid 34649612)
5. Bender, B. G., Rankin, A., Tran, Z. V., & Wamboldt, F. S. (2008). Brief-interval telephone surveys of medication adherence and asthma symptoms in the Childhood Asthma Management Program Continuation Study. Annals of Allergy, Asthma & Immunology, 101(4), 382-386.
6. Bisgaard, H., Loland, L., & Oj, J. A. (1999). NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. American Journal of Respiratory and Critical Care Medicine, 160(4), 1227-1231. (Pubitemid 29487463)
7. Bratton, D. L., Lanz, M. J., Miyazawa, N., White, C. W., & Silkoff, P. E. (1999). Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: A preliminary study. Pediatric Pulmonology, 28(6), 402-407. (Pubitemid 30017558)
8. Buchvald, F., Baraldi, E., Carraro, S., Gaston, B., De Jongste, J., Pijnenburg, M. W., Silkoff, P. E., & Bisgaard, H. (2005). Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. Journal of Allergy and Clinical Immunology, 115(6), 1130-1136. (Pubitemid 40824579)
9. Chowdhury, K. D., Sen, G., & Biswas, T. (2010). Regulatory role of nitric oxide in the reduced survival of erythrocytes in visceral leishmaniasis. Biochimica et Biophysica Acta, 1800(9), 964-976.
10. Conner, D. P. (2007). FDA correspondence from the office of generic drugs. Ref. No. OGD 06-0577.
11. FDA. Currie, G. P., Syme-Grant, N. J., McFarlane, L. C., Carey, F. A., & Lipworth, B. J. (2003). Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma. Allergy, 58(7), 602-607. (Pubitemid 36831314)
12. de Gouw, H.W., Hendriks, J.,Woltman, A. M., Twiss, I. M., & Sterk, P. J. (1998). Exhaled nitric oxide (NO) is reduced shortly after bronchoconstriction to direct and indirect stimuli in asthma. American Journal of Respiratory and Critical Care Medicine, 158(1), 315-319. (Pubitemid 28337197)
13. Dweik, R. A., Comhair, S. A., Gaston, B., Thunnissen, F. B., Farver, C., Thomassen, M. J., Kavuru, M., Hammel, J., Abu-Soud, H. M., & Erzurum, S. C. (2001). NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response. Proceedings of the National Academy of Sciences, 98(5), 2622-2627. (Pubitemid 32209532)
14. Dweik, R. A., Boggs, P. B., Erzurum, S. C., Irvin, C. G., Leigh, M. W., Lundberg, J. O., Olin, A. C., Plummer, A. L., & Taylor, D. R. (2011). An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. American Journal of Respiratory and Critical Care Medicine, 184(5), 602-615.
15. Evjenth, B., Hansen, T. E., & Holt, J. (2012). Exhaled nitric oxide decreases during exercise in nonasthmatic children. The Clinical Respiratory Journal. doi:10.1111/j.1752-699X.2012.00292.x.
16. FDA. (1995). Guidance for industry and FDA staff: Topical dermatologic corticosteroids. In: Vivo bioequivalence, D.o.B.i.t.O.o.G. Drugs. Editor 1995, FDA. (available from www.fda.gov)
17. FDA. (2003). Guidance for industry and FDA staff: Breath Nitric Oxide Test System. In: 1211. FDA, Editor 2003. (available from www.fda.gov)
18. Garbutt, J., Highstein, G., Nelson, K. A., Rivera-Spoljaric, K., & Strunk, R. (2009). Detection and home management of worsening asthma symptoms. Annals of Allergy, Asthma & Immunology, 103(6), 469-473.
19. GINA. (2011). Asthma management and prevention. Global initiative for Asthma. In: GINA, G.c.a. board, Editor 2011. pp. 1-124. (available from www. ginasthma.org).
20. Hahn, P. Y., Morgenthaler, T. Y., & Lim, K. G. (2007). Use of exhaled nitric oxide in predicting response to inhaled corticosteroids for chronic cough. Mayo Clinic Proceedings, 82(11), 1350-1355. (Pubitemid 350060130)
21. Hakonarson, H., & Halapi, E. (2002). Genetic analyses in asthma: Current concepts and future directions. American Journal of Pharmacogenomics, 2(3), 155-166. (Pubitemid 35167862)
22. Health Canada. (2011). Draft guidance document: Data requirements for safety and effectiveness of subsequent market entry inhaled corticosteroid products for use in the treatment of asthma. Public Work and Government Services Canada. (available from www.hc-sc.gc.ca)
23. Holgate, S., Bisgaard, H., Bjermer, L., Haahtela, T., Haughney, J., Home, R., Mclvor, A., Palkonen, S., Price, D. B., Thomas, M., Valovirta, E., & Wahn, U. (2008). The Brussels Declaration: The need for change in asthma management. European Respiratory Journal, 32(6), 1433-1442.
24. Jouaville, L. F., Annesi-Maesano, I., Nguyen, L. T., Bocage, A. S., Bedu, M., & Caillaud, D. (2003). Interrelationships among asthma, atopy, rhinitis and exhaled nitric oxide in a population-based sample of children. Clinical and Experimental Allergy, 33(11), 1506-1511. (Pubitemid 37421627)
25. Kharitonov, S. A., & Barnes, P. J. (2003). Nitric oxide, nitrotyrosine, and nitric oxide modulators in asthma and chronic obstructive pulmonary disease. Current Allergy and Asthma Reports, 3(2), 121-129. (Pubitemid 39467925)
26. Kharitonov, S. A., Robbins, R. A., Yates, D., Keatings, V., & Barnes, P. J. (1995). Acute and chronic effects of cigarette smoking on exhaled nitric oxide. American Journal of Respiratory and Critical CareMedicine, 152 (2), 609-612.
27. Kharitonov, S., Alving, K., & Barnes, P. J. (1997). Exhaled and nasal nitric oxide measurements:Recommendations. The European Respiratory Society Task Force. The European Respiratory Journal, 10(7), 1683-1693.
28. Kharitonov, S. A., Donnelly, L. E., Montuschi, P., Corradi, M., Collins, J. V., & Barnes, P. J. (2002). Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax, 57(10), 889-896. (Pubitemid 35178615)
29. Kim, S. H., Lee, S. L., & Lionberger, R. A. (2012). Application of the dose-scale method for pharmacodynamic bioequivalence studies of orally inhaled drug products in respiratory drug delivery 2012. Phoenix. In: Respiratory Drug Delivery, 2, 515-518.
30. Kissoon, N., Duckworth, L. J., Blake, K. V., Murphy, S. P., & Lima, J. J. (2002). Effect of beta2-agonist treatment and spirometry on exhaled nitric oxide in healthy children and children with asthma. Pediatric Pulmonology, 34(3), 203-208. (Pubitemid 34971073)
31. Lee, S. L. (2012). US Regulatory Considerations for generic dry powder inhalers. In: Respiratory drug delivery, 1, 317-324.
32. Loveless, M. O., Phillips, C. R., Giraud, G. D., & Holden, W. E. (1997). Decreased exhaled nitric oxide in subjects with HIV infection. Thorax, 52(2), 185-186. (Pubitemid 27086750)
33. Maniscalco, M., Vatrella, A., & Sofia, M. (2002). Passive smoke and exhaled nitric oxide. American Journal of Respiratory and Critical Care Medicine, 165(8), 1188. Author reply.
34. Marczin, N., Riedel, B., Royston, D., & Yacoub, M. (1997). Intravenous nitrate vasodilators and exhaled nitric oxide. Lancet, 349(9067), 1742. (Pubitemid 27252676)
35. Massaro, A. F., Gaston, B., Kita, D., Fanta, C., Stamler, J. S., & Drazen, J. M. (1995). Expired nitric oxide levels during treatment of acute asthma. American Journal of Respiratory and Critical Care Medicine, 152(2), 800-803.
36. Mehta, S., Stewart, D. J., & Levy, R. D. (1996). The hypotensive effect of L-arginine is associated with increased expired nitric oxide in humans. Chest, 109 (6), 1550-1555.
37. Meijer, R. J., Postma, D. S., Kauffman, H. F., Arends, L. R., Koëter, G. H., & Kerstjens, H. A. (2002). Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clinical and Experimental Allergy, 32(7), 1096-1103. (Pubitemid 34779609)
38. Narang, I., Ersu, R., Wilson, N. M., & Bush, A. (2002). Nitric oxide in chronic airway inflammation in children: Diagnostic use and pathophysiological significance. Thorax, 57(7), 586-589. (Pubitemid 34761759)
39. National Jewish Health. (2009). Consensus statement on the use of fractional exhaled nitric oxide (FeNo) in the clinical management of asthma. (available from www. nationaljewish.org)
40. Olin, A. C., Aldenbratt, A., Ekman, A., Ljungkvist, G., Jungersten,L., Alving,K., Torén,K. (2001). Increased nitric oxide in exhaled air after intake of a nitrate-rich meal. Respiratory Medicine, 95(2), 153-158. (Pubitemid 32624447)
41. Olin, A. C., Rosengren, A., Thelle, D. S., Lissner, L., Bake, B., & Torén, K. (2006). Height, age, and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample. Chest, 130(5), 1319-1325. (Pubitemid 44786722)
42. Olin, A. C., Bake, B., & Toren, K. (2007). Fraction of exhaled nitric oxide at 50 mL/s: Reference values for adult lifelong never-smokers.Chest, 131(6), 1852-1856. (Pubitemid 46981645)
43. Persson, M. G., Zetterström, O., Agrenius, V., Ihre, E., & Gustafsson, L. E. (1994). Single-breath nitric oxide measurements in asthmatic patients and smokers. Lancet, 343(8890), 146-147. (Pubitemid 24028642)
44. Pizzichini, M. M., Pizzichini, E., Clelland, L., Efthimiadis, A., Pavord, I., Dolovich, J., & Hargreave, F. E. (1999). Prednisone-dependent asthma: Inflammatory indices in induced sputum. European Respiratory Journal, 13(1), 15-21. (Pubitemid 29079213)
45. Redington, A. E., Meng, Q. H., Springall, D. R., Evans, T. J., Créminon, C., Maclouf, J., Holgate, S. T., Howarth, P. H., & Polak, J. M. (2001). Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment. Thorax, 56(5), 351-357. (Pubitemid 32398124)
46. Rolla, G., Colagrande, P., Scappaticci, E., Chiavassa, G., Dutto, L., Cannizzo, S., Bucca, C., Morello, M., Bergerone, S., Bardini, D., Zaccagna, A., Puiatti, P., Fava, C., & Cortese, G. (2000). Exhaled nitric oxide in systemic sclerosis: Relationships with lung involvement and pulmonary hypertension. Journal of Rheumatology, 27(7), 1693-1698. (Pubitemid 30462813)
47. Shaw, D. E., Berry, M. A., Thomas, M., Green, R. H., Brightling, C. E., Wardlaw, A. J., & Pavord, I. D. (2007). The use of exhaled nitric oxide to guide asthma management: A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine, 176(3), 231-237. (Pubitemid 47195872)
48. Silkoff, P. E., McClean, P. A., Slutsky, A. S., Caramori, M., Chapman, K. R., Gutierrez, C., & Zamel, N. (1998). Exhaled nitric oxide and bronchial reactivity during and after inhaled beclomethasone in mild asthma. The Journal of Asthma, 35(6), 473-479. (Pubitemid 28566102)
49. Silkoff, P. E., Wakita, S., Chatkin, J., Ansarin, K., Gutierrez, C., Caramori, M. M., McClean, P., Slutsky, A. S., Zamel, N., & Chapman, K. R. (1999). Exhaled nitric oxide after beta2-agonist inhalation and spirometry in asthma. American Journal of Respiratory and Critical Care Medicine, 159(3), 940-944. (Pubitemid 29137800)
50. Silkoff, P. E., McClean, P., Spino, M., Erlich, L., Slutsky, A. S., & Zamel, N. (2001). Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest, 119(5), 1322-1328. (Pubitemid 32686011)
51. Silkoff, P. E., Carlson, M., Bourke, T., Katial, R., Ogren, E., & Szefler, S. J. (2004). The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. The Journal of Allergy and Clinical Immunology, 114(5), 1241-1256. (Pubitemid 39469172)
52. Smith, A. D., Cowan, J. O., Brassett, K. P., Filsell, S., McLachlan, C., Monti-Sheehan, G., Herbison, G. P., & Taylor, D. R. (2005a). Exhaled nitric oxide: A predictor of steroid response. American Journal of Respiratory and Critical Care Medicine, 172(4), 453-459. (Pubitemid 41117391)
53. Smith, A. D., Cowan, J. O., Brassett, K. P., Herbison, G. P., & Taylor, D. R. (2005b). Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. The New England Journal of Medicine, 352 (21), 2163-2173.
54. Taylor, D. R., Pijnenburg, M. W., Smith, A. D., & De Jongste, J. C. (2006). Exhaled nitric oxide measurements: Clinical application and interpretation. Thorax, 61(9), 817-827. (Pubitemid 44369409)
55. Taylor, D. R., Mandhane, P., Greene, J. M., Hancox, R. J., Filsell, S., McLachlan, C. R., Williamson, A. J., Cowan, J. O., Smith, A. D., & Sears, M. R. (2007). Factors affecting exhaled nitric oxide measurements: The effect of sex. Respiratory Research, 8, 82.
56. van Amsterdam, J. G., Janssen, N. A., deMeer, G., Fischer, P. H., Nierkens, S., van Loveren, H., Oppenhuizen, A., Steerenberg, P. A., & Brunekreef, B. (2003). The relationship between exhaled nitric oxide and allergic sensitization in a random sample of school children. Clinical and Experimental Allergy, 33(2), 187-191. (Pubitemid 36241375)
57. Yates, D. H., Kharitonov, S. A., Thomas, P. S., & Barnes, P. J. (1996). Endogenous nitric oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase. American Journal of Respiratory and Critical Care Medicine, 154(1), 247-250. (Pubitemid 26255797)
58. Yates, D. H., Kharitonov, S. A., & Barnes, P. J. (1997). Effect of short-and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. European Respiratory Journal, 10(7), 1483-1488. (Pubitemid 27311059)
59. Yates, D. H., Breen, H., & Thomas, P. S. (2001). Passive smoke inhalation decreases exhaled nitric oxide in normal subjects. American Journal of Respiratory and Critical Care Medicine, 164(6), 1043-1046. (Pubitemid 32971656)
60. Zetterquist, W., Pedroletti, C., Lundberg, J. O., & Alving, K. (1999). Salivary contribution to exhaled nitric oxide. European Respiratory Journal, 13(2), 327-333. (Pubitemid 29086828)